How to appeal a Humana lymphoma & leukemia (heme malignancies) denial

The framework that applies to your appeal

Medicare Advantage plans follow a separate appeal track from commercial plans. Reconsideration must be requested within 60 days; if the plan misses its deadline, the case auto-forwards to the IRE (Maximus).

Humana-specific note: Heavily Medicare Advantage focused. MA-specific appeal track (42 CFR Part 422 Subpart M) applies — 60 days to request reconsideration, NOT the 180 days for commercial plans. Auto-forward to IRE (Maximus) if Humana misses deadline.

What Humana's policy requires for lymphoma & leukemia (heme malignancies)

Cited policy: Humana Reblozyl (Luspatercept-aamt) for Lower-Risk MDS and Beta-Thalassemia

Lower-risk MDS (IPSS-R Very Low / Low / Intermediate ≤3.5) — anemia / RBC transfusion-dependent. Aug 2023 expansion: 1L (no prior ESA required) per COMMANDS. Or post-ESA failure (MEDALIST). Beta-thalassemia transfusion-dependent. SC injection q3wk titrated 1.0 → 1.33 → 1.75 mg/kg. Hematologist Rx.

How Humana denies lymphoma & leukemia (heme malignancies) — and how to counter it

Where Humana pushes back: 1) Reblozyl 2L only — try ESA first; 2) Patient must be transfusion-dependent (≥4 units / 8 wk); 3) Hi-risk MDS not covered.

Counter-arguments that hold up: COMMANDS (Platzbecker Lancet 2023;402:373-385) — luspatercept SUPERIOR transfusion independence (58.5% vs 31.2%) + erythroid response vs epoetin alfa in 1L lower-risk MDS RBC-TD. FDA Aug 28, 2023 — 1L lower-risk MDS approval (no ESA failure required). NCCN MDS v3.2024 category 1 1L. MEDALIST (Fenaux NEJM 2020;382:140) prior 2L approval (Apr 3, 2020). For non-transfusion-dependent symptomatic anemia, ESA-first sequencing applies; for RBC-TD, Reblozyl 1L.

What Humana typically denies for lymphoma & leukemia (heme malignancies)

Across Humana's commercial and Medicare books, denials cluster around a small number of patterns. For lymphoma & leukemia (heme malignancies), expect:

• MA plan step therapy on Part B drugs
• Skilled nursing facility days
• Prior auth on specialty drugs
• OON emergency reduction

Treatments most often denied in this category

These are the lymphoma & leukemia (heme malignancies) treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Imbruvica
• Calquence
• Brukinsa
• Jaypirca / pirtobrutinib
• Venclexta
• Rituxan / rituximab

How to submit the appeal to Humana

1. Read the denial letter — note the exact denial reason code and the appeal deadline (60 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Humana cited in the denial.
3. File the appeal through Humana's portal (members: https://www.humana.com ; providers: https://www.humana.com/provider). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In KY, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Humana's prior-authorization criteria by drug: Humana PA criteria on ApprovalHelp.